Lanreotide vs Thymosin Alpha-1
Overview
Lanreotide is primarily a hormonal peptide, while Thymosin Alpha-1 is used for healing & recovery.
This page compares Lanreotide and Thymosin Alpha-1 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Lanreotide | Thymosin Alpha-1 | |
|---|---|---|
| Category | Hormonal | Healing & Recovery |
| Regulatory status (US) | FDA approved | Research use only |
| Typical dosage | 60-120 mg | 1.6-3.2 mg |
| Frequency | every 4 weeks | twice-weekly |
| Reported benefits | suppression of excess growth hormone and IGF-1 in acromegaly, improved progression-free survival in GEP-NETs, reduction of carcinoid syndrome symptoms, inhibition of multiple GI and pancreatic hormones | Immune enhancement, antiviral properties, chronic infection support, cancer therapy adjunct |
| Reported side effects | diarrhea, cholelithiasis, abdominal pain, hyperglycemia, bradycardia, injection site reactions, nausea, hypertension, headache, thyroid function decreases | Well-tolerated. Rare: injection site reactions, mild flu-like symptoms |
Key differences
Primary use. Lanreotide is categorised under Hormonal, while Thymosin Alpha-1 falls under Healing & Recovery. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Lanreotide: FDA-approved. Thymosin Alpha-1: not FDA-approved; treated as a research compound.
Dosing. Lanreotide is typically dosed at 60-120 mg (every 4 weeks). Thymosin Alpha-1 is typically dosed at 1.6-3.2 mg (twice-weekly).
Can you stack them?
Some protocols combine peptides, but stacking Lanreotide and Thymosin Alpha-1 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Lanreotide and Thymosin Alpha-1?
- Lanreotide is primarily a hormonal peptide, while Thymosin Alpha-1 is used for healing & recovery. Lanreotide is FDA-approved for one or more indications, whereas Thymosin Alpha-1 is not FDA-approved; generally classified as a research compound.
- What is Lanreotide used for?
- FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome.
- What is Thymosin Alpha-1 used for?
- Immune system support.
- Can you take Lanreotide and Thymosin Alpha-1 together?
- Some users combine peptides within a single protocol, but stacking Lanreotide and Thymosin Alpha-1 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Lanreotide or Thymosin Alpha-1 FDA-approved?
- Lanreotide is FDA-approved for one or more indications. Thymosin Alpha-1 is not FDA-approved; generally classified as a research compound.
Read the full articles
- Lanreotide — full monograph: mechanism, research, dosing & references
- Thymosin Alpha-1 — full monograph: mechanism, research, dosing & references